| Year |
Citation |
Score |
| 2023 |
Zhang Y, Doran C, Le TK, Dreyfus B, Kola N, Sylvester BE, Lal L, Penrod JR, Meadows Shropshire S. Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer. Future Oncology (London, England). PMID 36942686 DOI: 10.2217/fon-2022-1117 |
0.335 |
|
| 2021 |
Alatise OI, Knapp GC, Sharma A, Chatila WK, Arowolo OA, Olasehinde O, Famurewa OC, Omisore AD, Komolafe AO, Olaofe OO, Katung AI, Ibikunle DE, Egberongbe AA, Olatoke SA, Agodirin SO, ... ... Sylvester B, et al. Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications. 12: 6821. PMID 34819518 DOI: 10.1038/s41467-021-27106-w |
0.569 |
|
| 2020 |
Hanrahan AJ, Sylvester BE, Chang MT, Elzein A, Gao J, Han W, Liu Y, Xu D, Gao SP, Gorelick AN, Jones AM, Kiliti AJ, Nissan MH, Nimura CA, Poteshman AN, et al. Leveraging systematic functional analysis to benchmark an in silico framework distinguishes driver from passenger MEK mutants in cancer. Cancer Research. PMID 32641410 DOI: 10.1158/0008-5472.CAN-20-0865 |
0.343 |
|
| 2017 |
Gao J, Chang MT, Johnsen HC, Gao SP, Sylvester BE, Sumer SO, Zhang H, Solit DB, Taylor BS, Schultz N, Sander C. 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Medicine. 9: 4. PMID 28115009 DOI: 10.1186/S13073-016-0393-X |
0.415 |
|
| 2016 |
Gao J, Chang MT, Sylvester BE, Johnsen HC, Gao SP, Sumer SO, Solit DB, Taylor BS, Schultz N, Sander C. Abstract 3606: Identification of oncogenic mutation hotspots via three-dimensional proximity Cancer Research. 76: 3606-3606. DOI: 10.1158/1538-7445.Am2016-3606 |
0.492 |
|
| 2015 |
Sylvester BE, Vakiani E. Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases. Journal of Gastrointestinal Oncology. 6: 668-75. PMID 26697200 DOI: 10.3978/j.issn.2078-6891.2015.083 |
0.47 |
|
| 2015 |
Diamond EL, Durham BH, Haroche J, Yao Z, Ma J, Parikh SA, Wang Z, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol JB, Campbell P, Walsh MP, ... Sylvester B, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery. PMID 26566875 DOI: 10.1182/Blood.V126.23.481.481 |
0.325 |
|
| 2015 |
Grisham RN, Sylvester BE, Won H, McDermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolniy F, Makker V, Sala E, Soumerai TE, Hyman DM, Socci ND, et al. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26324360 DOI: 10.1200/JCO.2015.62.4726 |
0.544 |
|
| 2015 |
Grimm WA, Messer JS, Murphy SF, Nero T, Lodolce JP, Weber CR, Logsdon MF, Bartulis S, Sylvester BE, Springer A, Dougherty U, Niewold TB, Kupfer SS, Ellis N, Huo D, et al. The Thr300Ala variant in ATG16L1 is associated with improved survival in human colorectal cancer and enhanced production of type I interferon. Gut. PMID 25645662 DOI: 10.1136/Gutjnl-2014-308735 |
0.475 |
|
| 2015 |
Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1935-43. PMID 25351745 DOI: 10.1158/1078-0432.Ccr-14-2124 |
0.449 |
|
| 2015 |
Durham BH, Diamond EL, Haroche J, Yao Z, Ma J, Parikh SA, Choi J, Kim E, Cohen-Aubart F, Lee SC, Gao Y, Micol J, Campbell P, Walsh MP, Sylvester B, et al. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms Blood. 126: 481-481. DOI: 10.1182/blood.V126.23.481.481 |
0.379 |
|
| 2014 |
Brannon AR, Vakiani E, Sylvester BE, Scott SN, McDermott G, Shah RH, Kania K, Viale A, Oschwald DM, Vacic V, Emde AK, Cercek A, Yaeger R, Kemeny NE, Saltz LB, et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology. 15: 454. PMID 25164765 DOI: 10.1186/s13059-014-0454-7 |
0.544 |
|
| 2014 |
Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB. BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer Cancer. 120: 2316-2324. PMID 24737664 DOI: 10.1002/Cncr.28729 |
0.562 |
|
| 2012 |
Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling RV, Olugbile S, Polite BN, Olopade OI. Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 350-9. PMID 22114137 DOI: 10.1158/1078-0432.Ccr-11-1397 |
0.615 |
|
| 2012 |
Brannon AR, Vakiani E, Scott S, Sylvester B, Kania K, Viale A, Solit D, Berger M. Targeted next-generation sequencing of colorectal cancer identified metastatic specific genetic alterations Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S6-P3 |
0.375 |
|
| 2012 |
Miller ME, Kunnavakkam R, Khramtsova G, Khramtsov A, Sylvester B, Huo D, Olopade OI, Goss KH. Abstract B53: Analysis of Wnt signaling as a determinant of racial disparities in colorectal cancer outcomes. Cancer Epidemiology, Biomarkers & Prevention. 21. DOI: 10.1158/1055-9965.Disp12-B53 |
0.603 |
|
| 2011 |
Polite BN, Sylvester BE, Olopade OI. Race and subset analyses in clinical trials: time to get serious about data integration. Journal of the National Cancer Institute. 103: 1486-8. PMID 21997133 DOI: 10.1093/Jnci/Djr382 |
0.528 |
|
| 2010 |
Sylvester BE, Huo D, Khramtsov A, Zhang J, Smalling R, Polite B, Olopade OI. Abstract 28: Molecular analysis of colorectal cancer progression in an ethnically diverse cohort reveals a higher prevalence of KRAS mutations in African Americans Cancer Research. 70: 28-28. DOI: 10.1158/1538-7445.Am10-28 |
0.572 |
|
| Show low-probability matches. |